Immunology and inflammation

News

Cancer risk scuppers Kyowa Kirin's autoimmune disease drug

Kyowa Kirin has terminated all clinical trials of its anti-OX40L antibody rocatinlimab, after cases of cancer were seen in patients taking the drug.

News

Boehringer bets up to $500m on Sitryx immunology programme

Boehringer Ingelheim's partnership with Sitryx is focused on a family of small-molecule drugs for autoimmune and inflammatory diseases.

News

Novartis' oral BTK drug moves the needle in CINDU

Novartis is set to expand the label for its oral BTK inhibitor Rhapsido, keeping the drug on course to become one of its biggest-ever brands.

News

Takeda signs $1.7bn AI alliance with Iambic

Iambic bags another pharma partner, Takeda, which plans to use its AI platform to find drugs for cancer, gastrointestinal, and inflammatory disorders.

News

Lilly strikes $8.8bn-plus alliance with China's Innovent

Eli Lilly has deepened its ties with Chinese biopharma company Innovent Biologics, signing a seventh R&D with a $350m upfront payment.

News

Sanofi plans amlitelimab dermatitis filing after new readout

Sanofi has said it will press ahead with regulatory filings for atopic dermatitis candidate amlitelimab, despite mixed data in phase 3.

Cancer risk scuppers Kyowa Kirin's autoimmune disease drug

Boehringer bets up to $500m on Sitryx immunology programme

Novartis' oral BTK drug moves the needle in CINDU

Takeda signs $1.7bn AI alliance with Iambic

Lilly strikes $8.8bn-plus alliance with China's Innovent

Sanofi plans amlitelimab dermatitis filing after new readout

Which biotechs have raised new VC financing this week?

Discover a new era of healthcare panel engagement: Grounded ...

Immunology and inflammation

Editor's Picks